ストックスクリーナーアプリを入手
30.68
1.41%
-0.44
前日終値:
$31.12
開ける：
$30.8
24時間の取引高:
1.06M
Relative Volume:
0.71
時価総額：
$2.93B
収益：
$305.00K
当期純損益:
$-328.98M
株価収益率:
-7.1931
EPS:
-4.2652
ネットキャッシュフロー:
$-309.60M
1週間 パフォーマンス:
-3.76%
1か月 パフォーマンス:
+0.82%
6か月 パフォーマンス:
+101.44%
1年 パフォーマンス:
+55.26%
1日の値動き範囲:
$30.35
$31.54
1週間の範囲:
$30.35
$31.89
52週間の値動き範囲:
$9.90
$34.04
Viridian Therapeutics Inc Stock (VRDN) Company Profile
VRDN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
30.68 | 2.97B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 繰り返されました | Wedbush | Outperform |
| 2025-12-03 | 開始されました | William Blair | Outperform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 開始されました | TD Cowen | Buy |
| 2024-09-11 | 繰り返されました | Needham | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-05-09 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 開始されました | BTIG Research | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-05-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-17 | 開始されました | Wells Fargo | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2022-12-19 | 開始されました | Cowen | Outperform |
| 2022-12-19 | 開始されました | Needham | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-12-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-11-18 | 開始されました | SVB Leerink | Outperform |
| 2021-10-12 | 開始されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Viridian Therapeutics Inc (VRDN) 最新ニュース
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus
Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда
Published on: 2025-12-20 23:42:03 - Улправда
Will Viridian Therapeutics Inc. stock deliver consistent dividendsGlobal Markets & Weekly High Return Stock Forecasts - ulpravda.ru
FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm
Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber
Published on: 2025-12-19 16:37:51 - Улправда
Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Trends & Smart Money Movement Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail
Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com India
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts - ts2.tech
Viridian Therapeutics stock reaches 52-week high at 33.67 USD By Investing.com - Investing.com Nigeria
Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week HighShould You Buy? - MarketBeat
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
Understanding Momentum Shifts in (VRDN) - Stock Traders Daily
Maverick Capital Ltd. Grows Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. $VRDN Shares Sold by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Has $6.77 Million Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Velan Capital Investment Management LP Makes New $1.21 Million Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Wedbush - MarketBeat
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating - marketscreener.com
VRDN: Wedbush Raises Price Target to $47 While Maintaining Outpe - GuruFocus
Viridian Therapeutics, Inc. $VRDN Stock Position Lifted by Marshall Wace LLP - MarketBeat
Diadema Partners LP Has $1.71 Million Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
With Viridian Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Viridian Therapeutics Inc (VRDN) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):